Medication info

Rinagen Duo Tablets 2.5/1000 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Sungwon Adcock Pharmaceutical Co., Ltd.
Appearance
Bright pink, biconvex, oval, film-coated tablet
Packaging
60 tablets/PTP [10 tablets/PTP packaging x 6]
Approval status
Expired

MFDS item code 202001410 · Approved 2020.02.28

This product's status changed to Expired on 2025.02.28. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be taken twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug treatment who have difficulty achieving adequate glycemic control with monotherapy, the starting dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients unable to achieve adequate glycemic control with metformin monotherapy: The initial dose is linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients unable to achieve adequate glycemic control with combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients in whom the medicine should be administered with caution). 5. Patients unable to achieve adequate glycemic control with combination therapy with insulin and metformin: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients in whom the medicine should be administered with caution). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Patients in whom the medicine is contraindicated).

Ingredients

Manufacturer
Sungwon Adcock Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulty in blood sugar control
View approved original text

This medication is administered alongside dietary and exercise therapies to assist in blood sugar control for adults with type 2 diabetes. It is used in patients who have no prior experience with diabetes medication or have difficulty controlling blood sugar with metformin alone. Additionally, it is administered in combination with sulfonylurea when blood sugar control is difficult with either replacement therapy of linagliptin and metformin or maximum doses of metformin and sulfonylurea. If sufficient effect is not achieved with insulin and metformin combination therapy, it can be used alongside insulin, and it may also be added to combination therapy of metformin and empagliflozin. It is used to improve blood sugar control in various treatment situations.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be taken twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug treatment who have difficulty achieving adequate glycemic control with monotherapy, the starting dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients unable to achieve adequate glycemic control with metformin monotherapy: The initial dose is linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients unable to achieve adequate glycemic control with combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients in whom the medicine should be administered with caution). 5. Patients unable to achieve adequate glycemic control with combination therapy with insulin and metformin: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients in whom the medicine should be administered with caution). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Patients in whom the medicine is contraindicated).

Precautions

This medication can cause serious side effects such as lactic acidosis and requires careful monitoring. Lactic acidosis is a condition where there is an excessive accumulation of lactate in the blood, which can be harmful and requires prompt treatment. This drug should not be administered to patients with certain conditions or impaired kidney function. For example, patients with type 1 diabetes, severe kidney impairment, liver dysfunction, serious infections, or dehydration should not take this medication. It is also recommended that pregnant or breastfeeding women avoid using this medicine. This medication can cause hypoglycemia, so blood sugar levels should be monitored closely, especially when taken with other hypoglycemic agents. Kidney function is related to the excretion of this medicine, so regular kidney function tests should be conducted, and administration may need to be discontinued if kidney function declines. Patients with heart disease or a recent history of myocardial infarction should also use this drug with caution. During treatment, rare side effects such as acute pancreatitis or blistering dermatosis may occur, so patients should consult a physician immediately if related symptoms appear. Routine blood tests are necessary to monitor vitamin B12 levels, as prolonged use may lead to a decrease. Furthermore, this medication can interact with other drugs, so it is essential to inform a physician or pharmacist of any concurrent medications. If planning for pregnancy or already pregnant, alternative treatments should be considered, and avoidance during breastfeeding is recommended. It is not recommended for children under ten years of age or adolescents between the ages of ten and seventeen, as safety and efficacy have not been established. Elderly patients are at higher risk for renal impairment, so dosage adjustments and regular monitoring are necessary. In the event of overdose, the risk of lactic acidosis increases, necessitating immediate medical treatment and possibly blood dialysis. This medication should be kept out of reach of children, stored away from moisture, and not transferred to other containers.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficiency of vitamin B12
  • hypoglycemia
  • taste disorder
  • cough
  • decreased appetite
Show 106 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • gastroenteritis
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • constipation
  • upper abdominal pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • gastrointestinal disorders
  • irritable bowel syndrome
  • burning mouth syndrome
  • colitis
  • abdominal discomfort
  • dyspepsia
  • gastroesophageal reflux disease
  • gastritis
  • stomatitis
  • periodontitis
  • influenza
  • fever
  • facial swelling
  • fatigue
  • chest pain
  • cerebral infarction
  • speech disturbances
  • Alzheimer's dementia
  • drowsiness
  • anxiety
  • mood disorders
  • insomnia
  • depression
  • dizziness
  • pruritus
  • hypertension
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • cholelithiasis
  • hearing loss
  • erectile dysfunction
  • goiter
  • anemia
  • headache
  • sensory loss
  • dizziness
  • osteoarthritis
  • limb pain
  • arthralgia
  • musculoskeletal discomfort
  • myositis
  • myalgia
  • soft tissue mass
  • rotator cuff syndrome
  • male pattern baldness
  • diabetic foot
  • skin lesions
  • dermatitis
  • unstable angina
  • palpitations
  • dry eye
  • cataract
  • eye discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • stress urinary incontinence
  • hematuria
  • hypotension
  • flushing
  • hepatic steatosis
  • hearing loss
  • dizziness
  • benign prostatic hyperplasia
  • confusion state
  • nocturia
  • dermatitis
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture and should be stored in a tightly closed container. It is advisable to keep it at room temperature between 1°C and 30°C to maintain its efficacy for a longer duration.

Appearance and packaging

Appearance

Bright pink, biconvex, oval, film-coated tablet

Package unit

60 tablets/PTP [10 tablets/PTP packaging x 6]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.